Published by Oxford University Press 201. 0. GSTM1 Null and NAT2 Slow Acetylation Genotypes, Smoking Intensity, and Bladder Cancer Risk: Results from the New England Bladder Cancer Case-Control Study and

D ow nloaded from Associations between bladder cancer risk and NAT2 and GSTM1 polymorphisms have emerged as some of the most consistent findings in the genetic epidemiology of common metabolic polymorphisms and cancer, but their interaction with tobacco use, intensity, and duration remain unclear. In a New England population-based case-control study of urothelial carcinoma, we collected mouthwash samples from 1,088 of 1,171 cases (92.9%) and 1282 of 1418 controls (91.2%) for genotype analysis of GSTM1, GSTT1 and NAT2 polymorphisms. Odds ratios (ORs) and 95 % confidence intervals (CIs) of bladder cancer among New England Bladder Cancer Study subjects with one or two inactive GSTM1 alleles (i.e., the “null ” genotype) were 1.26 (0.85-1.88) and 1.54 (1.05-2.25), respectively (p-trend=0.008), compared to those with tw